Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2020 Nov;33(6):e14387.
doi: 10.1111/dth.14387. Epub 2020 Oct 19.

Clinical experience with adalimumab biosimilar imraldi in hidradenitis suppurativa

Federica Ricceri  1 , Elia Rosi  1 , Antonella Di Cesare  1 , Leonardo Pescitelli  1 , Maria Thais Fastame  1 , Francesca Prignano  1
Affiliations
Observational Study

Clinical experience with adalimumab biosimilar imraldi in hidradenitis suppurativa

Federica Ricceri et al. Dermatol Ther. 2020 Nov.

Abstract

Adalimumab is the only biologic therapy approved for the treatment of patients with hidradenitis suppurativa, a chronic and disabling skin condition. To date, there are no studies in the literature about the effectiveness of adalimumab biosimilar SB5 in hidradenitis suppurativa. The aim of this study was to evaluate its efficacy and safety. A retrospective observational study was performed in hidradenitis suppurativa adalimumab naive patients and in patients who were switched from the adalimumab originator. Eleven patients were included in the study. Our results support adalimumab SB5 as an effective and well tolerated drug, with a good interchangeability with its originator also for the treatment of hidradenitis suppurativa.

Keywords: SB5; adalimumab; biosimilar; hidradenitis suppurativa; imraldi.

PubMed Disclaimer

References

REFERENCES

    1. Martorell A, Garcia-Martinez FJ, Jimenez-Gallo D, et al. An update on hidradenitis suppurativa (part I): epidemiology, clinical aspects and definition of disease severity. Actas Dermosifiliogr. 2015;106:703-715.
    1. Zoumboulis CC, Dessai N, Emtestam L, et al. European S1 guideline for the treatment of hidradenitis supppurativa/acne inversa. J Eur Acad Dermatol Venereol. 2015;29:619-644.
    1. World Health Organization. 2009 Expert Committee on Biological Standardization. Guidelines on evaluation of similar biotherapeutic products (SBPs). http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEU.... Accessed February 19, 2015.
    1. European Medicines Agency. 2017. Imraldi 40 mg solution for injection: summary of product characteristics. http://www.ema.europa.eu/. Accessed July 4, 2018.
    1. Frampton JE. SB5: an adalimumab biosimilar. BioDrugs. 2018;32(5):507-510.

Publication types

MeSH terms

LinkOut - more resources